Qiang Yang
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$5.6MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $5.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 5, 2023 | NIH | SBIR Phase I Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation | $90K | GLYCOT THERAPEUTICS LLC |
| May 1, 2022 | NIH | SBIR Phase I Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation | $321K | GLYCOT THERAPEUTICS LLC |
| Apr 28, 2022 | NIH | SBIR Phase I Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation | $232K | GLYCOT THERAPEUTICS LLC |
| Jul 30, 2021 | NIH | SBIR Phase II Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins | $775K | GLYCOT THERAPEUTICS LLC |
| Jul 6, 2020 | NIH | SBIR Phase I Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins | $150K | GLYCOT THERAPEUTICS LLC |
| Mar 4, 2020 | NIH | SBIR Phase II Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity | $545K | GLYCOT THERAPEUTICS LLC |
| Aug 1, 2019 | NIH | SBIR Phase I Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins | $300K | GLYCOT THERAPEUTICS LLC |
| Jul 15, 2019 | NIH | SBIR Phase I Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins | $150K | GLYCOT THERAPEUTICS LLC |
| Apr 5, 2019 | NIH | SBIR Phase II Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity | $1.3M | GLYCOT THERAPEUTICS LLC |
| Apr 3, 2019 | NIH | SBIR Phase II Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity | $714K | GLYCOT THERAPEUTICS LLC |
| Apr 1, 2018 | NIH | SBIR Phase I Chemoenzymatic synthesis of stable isotope-labeled glycopeptides as internal standards for glycosylation quantitation | $293K | GLYCOT THERAPEUTICS LLC |
| Mar 23, 2018 | NIH | SBIR Phase I Chemoenzymatic synthesis of stable isotope-labeled glycopeptides as internal standards for glycosylation quantitation | $293K | GLYCOT THERAPEUTICS LLC |
| Aug 1, 2017 | NIH | SBIR Phase I Chemoenzymatic glycan remodeling of IVIG for improved anti inflammatory activity | $219K | GLYCOT THERAPEUTICS LLC |
| Jul 27, 2017 | NIH | SBIR Phase I Chemoenzymatic glycan remodeling of IVIG for improved anti-inflammatory activity | $219K | GLYCOT THERAPEUTICS LLC |
Peer ranks
Federal funding#224
Awards as PI#57
Patents#273
Companies
- GLYCOT THERAPEUTICS LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.